|
|
Post by mattyj7183 on Dec 7, 2017 3:12:34 GMT
I have been in this company for about 9 months and, based on their research and FDA approval feel like they could make a positive impact in with the opioid crisis while still making me some money (win/win). A Very low market cap which I think is vastly undervalued given their partnership with the National Institute on Drug Abuse (NIDA) and BioCoRx's upcoming January 24, 2018, pre-IND meeting with the FDA about their BICX102 drug. I wanted to put it out to all of you for thoughts/discussion which are more than welcome.
Overview
BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one proprietary counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. Additionally, we have expanded the support structure to include 12 months of a peer-support system utilizing trained recovery specialists. The company is also developing a patent-pending injectable form of naltrexone.
Most Recent Investor Presentation
Naltrexone Implant
While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment. While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism. The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine on the same day, without the cravings for alcohol. BICX Security Details
(From OTC Markets)Share Structure Market Value1 $21,411,626 a/o Dec 05, 2017 Authorized Shares 525,000,000 a/o Dec 01, 2017 Outstanding Shares 243,286,285 a/o Dec 01, 2017 Float 110,031,021 a/o Jun 27, 2016 |
|
|
|
Post by mattyj7183 on Dec 12, 2017 13:51:54 GMT
New release for those who are interested: BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx RecoveryANAHEIM, CA, Dec. 12, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc.(BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that CereCare, LLC, a company focused on facilitating the provisioning of leading edge treatment solutions to those suffering from substance use disorders and other brain related conditions, is going to become a strategic partner for the BioCorRx Recovery Program. As part of the agreement, CereCare and its principal backers will pay an upfront fee of $100,000 and receive restricted shares in BioCorRx(BICX) plus performance-based options for reaching certain milestones. CereCare will have exclusive distributorship rights for the BioCorRx Program in Nevada, subject to certain performance criteria. CereCare establishes and operates medical clinics under its CereCare – Center of Excellence™ brand that focuses on treating alcohol and opiate addictions, as well as other substance use disorders. CereCare operates clinics in Los Angeles, Sherman Oaks, California and Reno, Nevada with plans to open additional locations in Beverly Hills and Palm Springs, California, as well as upstate New York and Ft. Lauderdale, Florida. CereCare will offer the BioCorRx Recovery Program in these clinics. Brady Granier, CEO, President, and Director of BioCorRx(BICX), stated, “We have been working with CereCare since we announced the Serrano Kidney and Vascular Access Center would be the first clinic offering our program to the Hispanic market in Los Angeles, California. We believe CereCare is the perfect partner to become an authorized distributor of our program because they have seen the positive results of our program on patients, and we also feel that they have the resources and experience to take this to another level. We will be supporting them in rolling out our program into their clinics and look forward to building out a successful partnership.” Walter Marting, Managing Member of CereCare, stated, “We are pleased to be a strategic partner for the BioCorRx Recovery Program. We believe that the combination of BioCorRx Cognitive Behavioral Therapy (CBT) and the naltrexone implant is the best treatment modality for people who have opioid or alcohol use disorders. We are also in discussions with two major hospital groups and several large self-insured groups about offering this comprehensive treatment and recovery program to their patient and employee populations and covering the costs associated with the program. Our partners within CereCare have deep experience in the health care insurance and re-insurance industries and in establishing Centers of Excellence.” About CereCare, LLC CereCare, LLC is a Nevada corporation focused on facilitating the provisioning of leading edge treatment solutions to those suffering from substance use disorders and other brain related conditions. The company has teamed with leading scientists nation-wide to develop these treatment modalities, which uniquely focus on dysfunctional brain conditions and the pathways to treating these brain diseases. About BioCorRx(BICX) BioCorRx Inc. (BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc.(BICX) is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com. Safe Harbor Statement The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. |
|
|
|
Post by mattyj7183 on Dec 21, 2017 1:44:22 GMT
Not sure who all is really following this - but I'll take an up 23.68% day any day of the week. January 24th can't come soon enough.
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102Dec 19, 2017
OTC Disclosure & News Service
ANAHEIM, CA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has submitted its pre-Investigational New Drug (pre-IND) package to the U.S. Food and Drug Administration (FDA) for the Company's naltrexone implant, BICX102. BICX102 is the Company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.
The submitted pre-IND package provides the FDA with current information on BICX102, as well as the proposed development plan. The purpose of the meeting is to review the development plan and to seek the agency’s guidance on further development and commercialization of BICX102.
This pre-IND submission follows BioCorRx's recent announcement that the FDA has granted the Company a Type-B pre-IND meeting scheduled for January 24, 2018. As previously announced, the National Institute on Drug Abuse (NIDA) has agreed to attend the pre-IND meeting for BICX102 with the FDA. NIDA and National Institute on Alcohol Abuse and Alcoholism (NIAAA) have also received the documents which were submitted to the FDA.
Brady Granier, CEO, President, and Director of BioCorRx, commented, “We are pleased that BioCorRx® will be starting out the New Year with a meeting with the FDA. The submission of the pre-IND package is a major step that BioCorRx® has completed in its efforts to bring BICX102 to market. We thank all of our advisors and consultants for their tireless efforts in putting together a package that we feel will lead to a very productive meeting. We are pursuing the 505(b)(2) regulatory pathway, which we believe will be a more rapid and cost-effective route to approval. We are pleased that both NIDA and NIAAA are involved in this process and we look forward to the meeting with the FDA.”
About BioCorRx®
BioCorRx® Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx® Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx® Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
|
|
|
|
Post by guruzim on Jan 11, 2018 21:08:34 GMT
I put a little into this and I'm up 70%. Wish I'd put in a little more  I am in around $.10, hopefully you are in much lower. |
|
|
|
Post by guruzim on Jan 12, 2018 20:32:31 GMT
another 30% move today
|
|
|
|
Post by guruzim on Feb 7, 2018 16:24:11 GMT
Mattyj, what are you short and mid term thoughts on this? Did you get out or are you holding?
|
|
|
|
Post by mattyj7183 on Feb 8, 2018 2:12:50 GMT
I am still holding strong and steady and in a holding pattern until the 30 period after the Pre-IND meeting from Jan 24 is over. The FDA will provide BICX with meeting notes that I assume would be considered material, and thus a press release would be issued along with the notes.
|
|
|
|
Post by minwalles on Nov 9, 2021 20:14:28 GMT
I haven't been able to sleep properly for a week, what should I do, how do you fight this disease? I remember taking naltrexone every day. Thanks to this drug, I overcame alcohol addiction and, as a result, I got insomnia, which bothered me for about two years. And all because I divorced my wife. What a weakling I was! Even if you have some sad things happening in your life, do not take drugs or alcohol in any case. Otherwise, it will only get worse. As a former alcoholic, I say this. But I admit, it was damn difficult to stop drinking alcohol. I proved to myself that I am not a weak person, and I have willpower. Good health to all, and thank you very much for the article. At that time, I had not yet heard of such a drug. I've heard some people drink different teas and thus their sleep is much better, is that true? |
|
I am in around $.10, hopefully you are in much lower.
